Evaluating Equipment Utility and Innovation - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Evaluating Equipment Utility and Innovation
A survey shows satisfaction with utility and innovation in most solid dosage and parenteral drug-manufacturing equipment.

Pharmaceutical Technology
Volume 37, Issue 4, pp. 110-113

Image: STEVE ALLEN, getty images
Pharmaceutical Technology’s annual equipment and manufacturing survey gained the industry’s perspectives on trends in finished drug-product manufacturing and equipment. Respondents in both solid dosage and parenteral drug manufacturing were generally satisfied with the utility of existing equipment and the pace of innovation in meeting manufacturing needs. Most employ quality by design (QbD) to some extent, but respondents identified a range of challenges in implementing QbD. Responses also indicated trends in high-potency/high-containment manufacturing, process analytical technology (PAT), and continuous manufacturing.

Solid-dosage equipment

Figure 1: Utility of existing solid-dosage equipment in meeting needs (% of respondents).
The survey showed that existing solid-dosage equipment is generally meeting needs. Areas noted by more than 20% of respondents as needing significant improvement, however, included process control/automation, powder transfer/materials handling, and feeding/dispensing (see Figure 1). When asked if innovation is keeping pace with current and future needs, responses were similar, with the same three areas indicated as lacking solutions by 20% or more of respondents. Tablet compression stood out as a strongly innovative area, with 96% of respondents indicating that innovation is “excellent” or “good” for this equipment.

Parenteral equipment

Figure 2: Utility of existing parenteral equipment in meeting needs (% of respondents).
Users of parenteral equipment, likewise, are generally satisfied with existing equipment, as shown in Figure 2. Process control/automation and vials/cartridges fill-finish equipment, however, were two areas noted by 20% or more of respondents as needing significant improvement. In all segments, nearly 80-90% of respondents said that the pace of innovation was “good” or “excellent”.

High-containment/high-potency manufacturing

Just over half of respondents that are involved in high-containment/high-potency manufacturing had seen an increase in activity in this area in the past year. Approximately one quarter of respondents said system setup/changeover was the most challenging factor in high-containment/high-potency manufacturing, while another quarter identified getting materials into or out of the contained system during production as the most challenging. Others identified air flow (10%), air-flow changes (10%), environmental issues (10%), containment (10%), personnel protection (7%) and ergonomics (3%) as the most challenging factor in high-containment/high-potency manufacturing.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here